Goldman Sachs Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)

Goldman Sachs analyst Paul Choi reiterated a Buy rating and $8.00 price target on Gossamer Bio Inc. (NASDAQ: GOSS).

The analyst comments "GOSS underperformed vs. the broader group today (-7.0% vs XBI: -1.6%) following the announcement (link) that it has entered into an option agreement to potentially acquire Respira Therapeutics (private) whose leading pipeline candidate is RT234, an inhaled vardenafil dry powder therapy under investigation as an on demand (PRN) treatment for pulmonary hypertension (PH). Given that vardenafil is already approved and RT234 is another version of it with a dry powder inhaler delivery and phosphodiesterase type 5 (PDE5) mechanism of action, we view it as clinically derisked, but we think investors will look for further evidence on potential differentiation, clarity on the trial design for an on demand PAH treatment, and how it will fit into the treatment paradigm given existing treatments. We remain Buy rated on GOSS shares; PT at $8."

For an analyst ratings summary and ratings history on Gossamer Bio Inc. click here. For more ratings news on Gossamer Bio Inc. click here.

Shares of Gossamer Bio Inc. closed at $2.78 yesterday.

You May Also Be Interested In

• Jefferies Upgrades Kingspan Group PLC (KSP:ID) to Buy
• JPMorgan Downgrades Assicurazioni Generali SpA (G:IM) (ARZGY) to Neutral
• Jefferies Starts Tamarack Valley Energy Ltd. (TVE:CN) at Buy